ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)

Clinical trial NCT04044859 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT04044859
Sponsor: USWM CT, LLC
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Endometrial Cancer Esophageal Cancer Esophagogastric Junction (EGJ)Gastric (Stomach) Cancer Head and Neck Cancer Melanoma Ovarian Cancer Non-small Cell Lung (NSCLC)Urothelial Cancer

Start date: 2019-08-20
Primary completion: 2026-12-23
Enrollment: 120

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.